WS7.5 Prolonged improvement in lung function and quality of life in cystic fibrosis: a 24-week extension study of levofloxacin nebulization solution (APT-1026) versus tobramycin nebulization solution in stable CF patients with chronic Pseudomonas aeruginosa infection

Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis

Future Microbiology ◽

10.2217/fmb-2021-0150 ◽

2021 ◽

Author(s):

J Stuart Elborn ◽

Patrick A Flume ◽

Donald R Van Devanter ◽

Claudio Procaccianti

Keyword(s):

Quality Of Life ◽

Cystic Fibrosis ◽

Pseudomonas Aeruginosa ◽

Lung Function ◽

Standard Care ◽

Bacterial Infections ◽

Pulmonary Infections ◽

Pseudomonas Aeruginosa Infection

People with cystic fibrosis (CF) are highly susceptible to bacterial infections of the airways. By adulthood, chronic Pseudomonas aeruginosa ( Pa) is the most prevalent infective organism and is difficult to eradicate owing to its adaptation to the CF lung microenvironment. Long-term suppressive treatment with inhaled antimicrobials is the standard care for reducing exacerbation frequency, improving quality of life and increasing measures of lung function. Levofloxacin (a fluoroquinolone antimicrobial) has been approved as an inhaled solution in Europe and Canada, for the treatment of adults with CF with chronic P. aeruginosa pulmonary infections. Here, we review the clinical principles relating to the use of inhaled antimicrobials and inhaled levofloxacin for the management of P. aeruginosa infections in patients with CF.

Download Full-text

Eradication of Pseudomonas aeruginosa with inhaled colistin in adults with non-cystic fibrosis bronchiectasis

Chronic Respiratory Disease ◽

10.1177/1479973119872513 ◽

2019 ◽

Vol 16 ◽

pp. 147997311987251 ◽

Cited By ~ 2

Author(s):

Marina Blanco-Aparicio ◽

Jesús Luis Saleta Canosa ◽

Paz Valiño López ◽

María Teresa Martín Egaña ◽

Iria Vidal García ◽

...

Keyword(s):

Quality Of Life ◽

Cystic Fibrosis ◽

Pseudomonas Aeruginosa ◽

Cohort Study ◽

Lung Function ◽

Eradication Rate ◽

Hospital Admissions ◽

Poor Quality ◽

The Mean

The persistent isolation of Pseudomonas aeruginosa in the airways of non-cystic fibrosis bronchiectasis (NCFB) patients is associated with a worsening of the symptoms, increase of exacerbations, poor quality of life and functional impairment. The objective of this study was the analysis of the eradication rate of P. aeruginosa in the sputum of patients with NCFB treated with inhaled colistin and the effects of the treatment in the exacerbations. This was a prospective, cohort, study of 67 NCFB patients treated with inhaled colistin at the Hospital of A Coruña (Spain). We recorded dyspnoea, exacerbations, lung function and sputum cultures of P. aeruginosa in the patients. The mean age of the patients was 67.25 ± 14.6 years (59.7% male). The percentages of eradication of P. aeruginosa in sputum at 3, 6, 9 and 12 months were 61.2%, 50.7%, 43.3% and 40.3%, respectively. We observed a significant decrease in exacerbations after 1 year of colistin treatment (1.98 ± 3.62) versus the previous year (3.40 ± 4.21, p < 0.001). We conclude that treatment with inhaled colistin in patients with NCFB and P. aeruginosa in sputum can achieve high rates of eradication even in patients with several previous positive cultures, as well as a significant decrease of exacerbations and hospital admissions.

Download Full-text

Physical Activity and Sedentary Behavior in Adults With Cystic Fibrosis: Association With Aerobic Capacity, Lung Function, Sleep, Well-Being, and Quality of Life

Respiratory Care ◽

10.4187/respcare.09270 ◽

2021 ◽

pp. respcare.09270

Author(s):

Máire Curran ◽

Audrey C Tierney ◽

Brenda Button ◽

Louise Collins ◽

Lauren Kennedy ◽

...

Keyword(s):

Quality Of Life ◽

Physical Activity ◽

Cystic Fibrosis ◽

Lung Function ◽

Sedentary Behavior ◽

Aerobic Capacity ◽

Well Being

Download Full-text

Effects of aerobic interval training on glucose tolerance in children and adolescents with cystic fibrosis: a randomized trial protocol

Trials ◽

10.1186/s13063-019-3803-8 ◽

2019 ◽

Vol 20 (1) ◽

Author(s):

Karolinne Souza Monteiro ◽

Matheus de Paiva Azevedo ◽

Lucas Menescal Jales ◽

Fernanda Elizabeth Pereira da Silva ◽

Ricardo Fernando Arrais ◽

...

Keyword(s):

Quality Of Life ◽

Cystic Fibrosis ◽

Lung Function ◽

Glucose Tolerance ◽

Children And Adolescents ◽

Interval Training ◽

Moderate Intensity ◽

Registration System ◽

Aerobic Interval Training

Abstract Background Individuals with cystic fibrosis (CF) may develop CF-related diabetes (CFDR). This comorbidity is related to a poorer quality of life, microvascular complications, a decline in lung function, and an increase in exacerbations, as well as delayed growth and puberty. Evidence exists that physical exercise contributes to glycemic control in individuals with non-CF-related diabetes. This exercise is usually continuous with moderate intensity and long duration, which can cause muscle dyspnea and fatigue in CF individuals. Aerobic interval training (AIT) emerges as a safe and effective alternative for treating these individuals. The objective of this study is to evaluate the effects of AIT on glucose tolerance in children and adolescents with CF. Methods This study will be a two-arm, prospectively registered, randomized controlled trial with blind assessors and twenty 6- to 18-year-old individuals with cystic fibrosis (CF) from two different Brazilian states. People with CF will be randomly allocated to either the experimental or control group using block randomization, stratified by puberty stage,. Participants from both groups will receive an educational intervention and will be asked to continue their usual daily treatment for the full duration of the study. Those in the experimental group will perform AIT on a cycle ergometer at home three times a week, for 8 consecutive weeks. The sample characterization will include an assessment of puberty stage, socioeconomic status, dyspnea, and anthropometry. The primary outcome will be the change in glucose tolerance, while the secondary outcomes will include lung function, exercise tolerance, respiratory muscle strength, quality of life, and CF exacerbations. All outcomes will be assessed at baseline, week 9, and week 17. Discussion This is the first study to evaluate the effects of AIT on glucose tolerance in children and adolescents with CF. This study will serve as a basis for guiding clinical practice and decision-making in treating glucose intolerance and CF-related diabetes (CFRD) in children and adolescents with CF. Trial registration ClinicalTrials.gov Protocol Registration System: NCT03653949. Registered on August 31, 2018.

Download Full-text